181 related articles for article (PubMed ID: 17379472)
1. Hepatitis C management by addiction medicine physicians: results from a national survey.
Litwin AH; Kunins HV; Berg KM; Federman AD; Heavner KK; Gourevitch MN; Arnsten JH
J Subst Abuse Treat; 2007 Jul; 33(1):99-105. PubMed ID: 17379472
[TBL] [Abstract][Full Text] [Related]
2. Substance abuse treatment and receipt of liver specialty care among persons coinfected with HIV/HCV who have alcohol problems.
Palepu A; Cheng DM; Kim T; Nunes D; Vidaver J; Alperen J; Saitz R; Samet JH
J Subst Abuse Treat; 2006 Dec; 31(4):411-7. PubMed ID: 17084795
[TBL] [Abstract][Full Text] [Related]
3. Hazardous alcohol consumption and other barriers to antiviral treatment among hepatitis C positive people receiving opioid maintenance treatment.
Watson B; Conigrave KM; Wallace C; Whitfield JB; Wurst F; Haber PS
Drug Alcohol Rev; 2007 May; 26(3):231-9. PubMed ID: 17454012
[TBL] [Abstract][Full Text] [Related]
4. A hepatitis A, B, C and HIV prevalence and risk factor study in ever injecting and non-injecting drug users in Luxembourg associated with HAV and HBV immunisations.
Removille N; Origer A; Couffignal S; Vaillant M; Schmit JC; Lair ML
BMC Public Health; 2011 May; 11():351. PubMed ID: 21595969
[TBL] [Abstract][Full Text] [Related]
5. Perceived barriers related to testing, management and treatment of HCV infection among physicians prescribing opioid agonist therapy: The C-SCOPE Study.
Litwin AH; Drolet M; Nwankwo C; Torrens M; Kastelic A; Walcher S; Somaini L; Mulvihill E; Ertl J; Grebely J
J Viral Hepat; 2019 Sep; 26(9):1094-1104. PubMed ID: 31074167
[TBL] [Abstract][Full Text] [Related]
6. Family medicine-directed hepatitis C care and barriers to treatment: a mixed-methods study.
von Aesch Z; Craig-Neil A; Shah H; Antoniou T; Meaney C; Pinto AD
CMAJ Open; 2021; 9(1):E201-E207. PubMed ID: 33688028
[TBL] [Abstract][Full Text] [Related]
7. The Hepatitis C Awareness Through to Treatment (HepCATT) study: improving the cascade of care for hepatitis C virus-infected people who inject drugs in England.
Harrison GI; Murray K; Gore R; Lee P; Sreedharan A; Richardson P; Hughes AJ; Wiselka M; Gelson W; Unitt E; Ratcliff K; Orton A; Trinder K; Simpson C; Ryder SD; Oelbaum S; Foster GR; Christian A; Smith S; Thomson BJ; Reynolds R; Harris M; Hickman M; Irving WL
Addiction; 2019 Jun; 114(6):1113-1122. PubMed ID: 30694582
[TBL] [Abstract][Full Text] [Related]
8. Physicians' attitudes and practice toward treating injection drug users with hepatitis C: results from a national specialist survey in Canada.
Myles A; Mugford GJ; Zhao J; Krahn M; Wang PP
Can J Gastroenterol; 2011 Mar; 25(3):135-9. PubMed ID: 21499577
[TBL] [Abstract][Full Text] [Related]
9. Age and gender-specific hepatitis C continuum of care and predictors of direct acting antiviral treatment among persons who inject drugs in Seattle, Washington.
Corcorran MA; Tsui JI; Scott JD; Dombrowski JC; Glick SN
Drug Alcohol Depend; 2021 Mar; 220():108525. PubMed ID: 33461152
[TBL] [Abstract][Full Text] [Related]
10. Psychiatric management of HIV/HCV-coinfected patients beginning treatment for hepatitis C virus infection: survey of provider practices.
Weiss JJ; Morgello S
Gen Hosp Psychiatry; 2009; 31(6):531-7. PubMed ID: 19892211
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C screening and referral for further investigation and treatment in a tertiary care hospital.
İskender G; Mert D; Çeken S; Bahçecitapar M; Yenigün A; Ertek M
J Infect Dev Ctries; 2020 Jun; 14(6):642-646. PubMed ID: 32683355
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of and risk factors for hepatitis C virus antibody among people who inject drugs in Cambodia: a national biological and behavioral survey.
Yi S; Mun P; Chhoun P; Chann N; Tuot S; Mburu G
Harm Reduct J; 2019 Apr; 16(1):29. PubMed ID: 31036011
[TBL] [Abstract][Full Text] [Related]
13. Under one roof: identification, evaluation, and treatment of chronic hepatitis C in addiction care.
Martin SA; Bosse J; Wilson A; Losikoff P; Chiodo L
Addict Sci Clin Pract; 2018 Apr; 13(1):10. PubMed ID: 29690936
[TBL] [Abstract][Full Text] [Related]
14. Management of hepatitis C in decentralised versus centralised drug substitution programmes and minimally invasive point-of-care tests to close gaps in the HCV cascade.
Bregenzer A; Conen A; Knuchel J; Friedl A; Eigenmann F; Näf M; Ackle P; Roth M; Fux CA
Swiss Med Wkly; 2017; 147():w14544. PubMed ID: 29185250
[TBL] [Abstract][Full Text] [Related]
15. 'Treat my whole person, not just my condition': qualitative explorations of hepatitis C care delivery preferences among people who inject drugs.
Tsui JI; Barry MP; Austin EJ; Sweek EW; Tung E; Hansen RN; Ninburg M; Scott JD; Glick SN; Williams EC
Addict Sci Clin Pract; 2021 Aug; 16(1):52. PubMed ID: 34384494
[TBL] [Abstract][Full Text] [Related]
16. Epidemiological survey of hepatitis C virus infection in a cohort of patients from a ser.T in naples, Italy.
Curcio F; Villano G; Masucci S; Plenzik M; Veneruso C; De Rosa G
J Addict Med; 2011 Mar; 5(1):43-9. PubMed ID: 21769046
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis B virus and hepatitis C virus services offered by substance abuse treatment programs in the United States.
Bini EJ; Kritz S; Brown LS; Robinson J; Calsyn D; Alderson D; Tracy K; McAuliffe P; Smith C; Rotrosen J
J Subst Abuse Treat; 2012 Jun; 42(4):438-45. PubMed ID: 22035702
[TBL] [Abstract][Full Text] [Related]
18. Benefits and adverse effects of hepatitis C screening: early results of a screening program.
Trepka MJ; Zhang G; Leguen F; Obiaja K; Malow RM; De La Rosa M
J Public Health Manag Pract; 2007; 13(3):263-9. PubMed ID: 17435493
[TBL] [Abstract][Full Text] [Related]
19. Meeting vaccination quality measures for hepatitis A and B virus in patients with chronic hepatitis C infection.
Kramer JR; Hachem CY; Kanwal F; Mei M; El-Serag HB
Hepatology; 2011 Jan; 53(1):42-52. PubMed ID: 21254161
[TBL] [Abstract][Full Text] [Related]
20. Using latent class analysis to identify patterns of hepatitis C service provision in drug-free treatment programs in the U.S.
Strauss SM; Rindskopf DM; Astone-Twerell JM; Des Jarlais DC; Hagan H
Drug Alcohol Depend; 2006 Jun; 83(1):15-24. PubMed ID: 16289523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
